Study of Radiation Therapy Treatment Effect in Pain Management for Metastatic Breast Cancer in RICK
Lara Abdelmunim IA*, Mohamed E Gar Elanabi, Nahla Gafer

College of Medical Radiological Science, Sudan university of Science and Technology, Khartoum, Sudan

*Corresponding author: Lara Abdelmunim IA
DOI: 10.21276/sjams.2019.7.4.2

Abstract
Pain is one of the most common, unattended and unsolved problem for the cancer patients. Radiotherapy is successful, time efficient, well tolerated. The goal of palliative radiotherapy symptoms relief at the site of primary tumor or from metastatic lesion. The study examined the association between Palliative radiotherapy and the improvement of the symptoms associated with metastatic breast cancer. These include metastatic in the spinal cord, bone and associated pain, also dealt with the connection between it and the improvement of the standard of life of the patient and toxic and other important factors and was achieved through a set of international standards questionnaire by which the calibration of the result. This study was conducted in the center of tumors treatment in Sudan, represented in Khartoum oncology hospital (RICK) in the period 2014 to 2017. The findings support the hypothesis that radiotherapy is an effective treatment for a proportion of patients with MBC related pain, with 35% of assessable patients experiencing a clinically meaningful improvement in their pain. Of these, 12.5% had a complete improvement in their pain. There were no specific features that differentiated the complete responders from the other number of patients though this may be due to the small number of complete responders.

Keywords: Palliative radiotherapy, pain management, metastic breast cancer, pain response.

INTRODUCTION
Metastatic breast cancer (MBC) is incurable, but still treatable, especially if there are limited metastases. The intent of treatment is palliative, providing symptomatic relief and optimization of the length and quality of life. Median survival is approximately 18 to 24 months in these patients. About 34–50% of patients receiving radiotherapy are of palliative intent [1]. Similar to other clinical domains, the practice of palliative radiotherapy is always guided by basic ethical principles and available clinical evidence. It requires sophisticated assessment to balance the potential benefits and burdens to the patients with respect to patient’s autonomy and expectations, and consideration of logistical factors. Palliative radiotherapy is mainly indicated to relieve various local symptoms in cancer patients; to prevent debilitation such as spinal cord compression and pathological fracture; and to achieve durable loco regional control [2] in table 1. The effectiveness has been confirmed by cumulative clinical evidence. For metastatic bone pain, palliative radiotherapy can achieve an overall pain response rate of 59–62%, and a complete pain response rate of 32–34%.

For multiple brain metastases, the overall response rate to external irradiation is around 60% with 30–40% achieving marked neurological improvement
**Table-1: Indication of palliative radiotherapy**

<table>
<thead>
<tr>
<th>Pain aspect</th>
<th>Indication for palliative radiotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metastatic bone pain</td>
<td>Thoracic tumours: SVCO, Upper airway obstruction, Dysphagia, Collapse of lung</td>
</tr>
<tr>
<td>Painful lymphadenopathy</td>
<td>Reduced the increased intracranial pressure secondary to brain metastases</td>
</tr>
<tr>
<td>Pain due to soft tissue infiltration by cancers</td>
<td>Retropertioneal tumours, Relief of hydronephrosis</td>
</tr>
<tr>
<td>Neuropathic pain due to nerve compression and infiltration</td>
<td>Pelvic tumours, Relief of hydronephrosis, Urinary retention, Intestinal obstruction</td>
</tr>
<tr>
<td>Rescue of neurological deficit</td>
<td>Control of fungation and ulceration of metastatic or primary skin cancers</td>
</tr>
<tr>
<td>Spinal cord compression</td>
<td>Haemostasis: Haemoptysis, Bleeding rectal or gynaecological cancers, Bleeding skin cancers</td>
</tr>
<tr>
<td>Brain metastases</td>
<td>Prophylaxis of impending symptoms, Prevention of spinal cord compression, Prevention of pathological fracture, Prevention of pending pressure symptoms</td>
</tr>
<tr>
<td>Relief of pressure symptoms</td>
<td>Durable control of advanced locoregional disease beyond cure</td>
</tr>
</tbody>
</table>

**Principle of Palliative Radiotherapy**

The intention of giving radiotherapy for palliation of symptoms is improvement in quality of life by decreasing or eradicating symptoms. This will not be achieved if the treatment itself induces a lot of side effects. Also, patients with metastatic cancer have a reduced life span, this may only be months, and therefore the treatment itself should not consume a major portion of the patients remaining lifespan. The major benefit of radiotherapy is the speed with which symptom improvement develops and the certainty of response. Sufficient radiation dose must be given to ensure that the symptom response will last for the rest of the patient’s life. Too low a dose means retreatment at some later time is needed. Hence guiding principles are:

- Accurate anatomical localization of the symptomatic tumor deposit.
- Simple treatment techniques and field arrangements.
- Short hypo fractionated treatment regimes.
- Moderate dose treatment to achieve a good predictable response and to keep treatment toxicity to a minimum.
- Consider the patient’s overall life expectancy when determining the treatment aims and the treatment duration.

**Radiotherapy for the Treatment of MBC**

Palliative radiation therapy for metastatic breast cancer can generally be performed with simple techniques and simple technology. The radiation treatment process is complex and consists of multiple steps. These are broadly summarized in a simplified form in Figure 3. The steps are not always necessarily in the same order nor are all the steps always needed. The latter is especially true for palliative radiation therapy where CT scanning and target volume delineation are not always required, particularly when a large fields are used to treat systemic disease or pain.
The Role of Palliative RT in metastatic breast cancer

MBC

Bone Pain and Bone Metastasis

The skeleton is one of the commonest sites for metastatic cancer of any type. Whilst cancer in the bones is not usually directly life threatening it is frequently a source of pain which is a major debility. On occasions the more disabling complication of pathological fracture, spinal cord compression and hypocalcaemia may also occur. Local irradiation of one or more painful bone deposits is associated with a high probability of pain relief.

However, other studies show that longer term pain relief, greater tumor shrinkage, and thus, fewer episodes of retreatment are achieved by a multifraction treatment program. Hence the choice of dose and fraction number needs to be tailored to the patient’s general condition, expected survival and convenience of access. While single dose treatment may be adequate for pain relief, when tumor shrinkage is the goal this may not be adequate. For example, in spinal cord compression, where extension of soft tissue tumor from the vertebral bone into the spinal canal causing the spinal cord to be compressed and neurological impairment, or in a weight bearing bone, where sufficient bone destruction has occurred to reduce the mechanical strength of the bone. In these situations significant tumor shrinkage is required to relieve symptoms.

So, short course fractionated treatment is preferred either 30Gy in 10 factions or 20Gy in 5 fractions per weeks.

Treatment planning of MBC in spinal cord compression

It occurs in three sites:
Thoracic spine 60%
Lumbosacral spine 30%
Cervical spine 10%

Immobilization

Body cushion with comfortable prone head rest

Field Arrangement

Prescribe at 5-8cm depending on particular level in cord (cervical – lumbar)
Field arrangement
Laterally
1 cm margin beyond the pedicle to cover the spinal cord and meninges along the nerve root up to the spiral ganglia

Caudal
1 cm below the termination of the sac L5-S3

Technique use to treat MSCC
- SSD
- Gantry angle = 0

Dose
Treat extradural disease – visualize on MRI + 2 vertebral bodies
- 8Gy / 1F
- 20 Gy / 5F / 5 days
- 30 Gy / 10F / 2 weeks

Indicated of Radiotherapy treatment of bone irradiation
- Bone metastases presenting with pain not adequately controlled by analgesia
- Bone metastases causing mass effect
- Inoperable impending / existing pathological fracture

Immobilization
- Pathological fracture following surgical fixation
- Head / C-Spine
- Thermoplastic Shell
- Extremities: may benefit from Body foam
Table 2

<table>
<thead>
<tr>
<th>Site</th>
<th>Patient position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Head</td>
<td>Supine, prone for posterior lesions, head rest</td>
</tr>
<tr>
<td>Spine:</td>
<td>Prone if patient able (otherwise supine), head rest</td>
</tr>
<tr>
<td>Pelvis</td>
<td>Supine</td>
</tr>
<tr>
<td>Extremities</td>
<td>Treatment site to be positioned away from normal tissue</td>
</tr>
<tr>
<td>Scapula</td>
<td>Supine unless mark-up on-set</td>
</tr>
<tr>
<td>Ribs</td>
<td>Dependent on site of rib metastasis to be treated</td>
</tr>
<tr>
<td>Sternum</td>
<td>Supine</td>
</tr>
</tbody>
</table>

**Target Definition**

The GTV = the volume of metastatic disease, as determined by diagnostic imaging and clinical examination

The CTV = The GTV + surrounding bone at risk of microscopic involvement. The PTV = The CTV with a margin dependent on the treatment site. Field borders should cover the area of metastatic involvement (the CTV) with a 1-3 cm margin while making anatomical considerations to aid future matching of fields and to avoid treatment of normal tissues. For post-operative treatment, the field should include metalwork with a 12 cm margin.

**Prescription Dose**

1- 6 Gy/1 F: Upper hemi body irradiation
2- 8 Gy/1 F: Standard dose for palliation of painful bone metastasis
3- 20 Gy/5 F: May be considered instead of single fraction for patients with a very good performance status with:
   - Inoperable impending pathological fracture
   - Established pathological fracture
   - Prior surgical fixation
   - Re irradiation of bone metastases
   - Large field size with a significant volume of normal tissue
4- 30 Gy/10 F: May be considered for patients with a good performance status and good prognosis (e.g. solitary bone metastasis from breast carcinoma)
5- 25 Gy/5 F: Radio biologically equivalent to 30 Gy in 10 F. May be considered for patients with a good performance status and good prognosis with a tumor with a high fraction sensitivity / low a/ß ratio [10].

**Materials and Methods**

The study was conducted at Khartoum oncology hospital (RICK). The study conducted from 2014 to 2017. The rationale for this study is to develop tools to assess and evaluate patients with late stage breast cancer in symptoms control by using symptoms improvement ratio (SIR) to evaluate the benefit of RT in palliative cases, what is mean by this is that now, in principle it is possible to evaluate the radiotherapy protocol by using simple and fast tools such as questionnaire, clinical follow up. The patients were planning and treatment by A fluoroscopy of patient by using simple planning with two image AP/PA-LAT view of patients to detect the patient separation the images were performed using two type of machine (Hustise Casitter unit, Terasix UPJ machine) the patients were planning depended on area of metastatic. Some cases were planning manual depending on previous patients images and anatomical land mark the patients were treated in both cobalt 60 unit or linear accelerator unit. It is analytical study where the data collected prospectively which was amongst the metastatic breast cancer patients in Sudan. Study of radiotherapy regimes for the treatment of in patients with MBC. A study schema is shown in Figure 4.
Pre study assessment

One of the challenges of conducting a study examining a pain intervention in patients with advanced cancer is that changes in analgesia may occur during the study period. In such cases, it becomes very difficult to disentangle any improvements in pain as a result of the study intervention from any changes in concomitant analgesia. One of the ways this can be addressed is by stabilizing pain and analgesia prior to study entry. This approach was adopted for potential.

Patients in this study. Prior to study consent, patients were reviewed by Drs. Nahla gaffer and Dr Mohaga (Palliative Medicine), often with multiple visits or telephone consultations over several weeks, enabling background analgesia to be optimized and pain stabilized, where possible, before study entry. This also resulted in some patients analgesia improving to the extent that their pain was no longer severe enough for study entry. Following optimization of analgesics, if patients were eligible, written informed consent was obtained.

Baseline visit at the baseline visit, an assessment of performance status was made along with a physical examination. All previous treatments for Metastatic breast cancer MBC–surgery, chemotherapy or radiotherapy - were documented along with the medication history which listed all medicines taken in the previous 24 hours. Baseline toxicity assessment was performed and all study questionnaires were completed. In order to improve compliance, rather than leaving the patient to complete the questionnaires, a researcher completed the questionnaires based on the answers received from the patient. Take blood samples from patients at baseline and week 12. The aims of these blood tests were twofold. The first aim was to explore the possibility that proteins could be identified which might help to predict a response to radiotherapy. The second aim was to explore the possibility of toxicity due to radiotherapy. Week 1 visit Patients were seen eight (+/-three) days after the start of radiotherapy for their week 1 visit. At this consultation, current medication was recorded, including analgesics in the past 24 hours. Any toxicity from radiotherapy was documented and the questionnaires were repeated. Current symptoms were documented following the week 1 visit, patients received weekly phone calls in order to monitor symptoms and assess analgesic requirements. Week 5 visit: Patients were seen 35 (+/-5) days from the start of radiotherapy. At this visit, all the study visits performed at week 1 were repeated. In
addition. However, if patients were unable to attend, efforts were made to see them at home. After the week 5 visit, the weekly phone calls continued until the week 12 visit. Week 12 visit: At the week 12 visit, all assessments undertaken at week 5 were repeated. Following this visit, patients were discharged back to their local oncology teams and study involvement ceased. During the course of the study, if patients’ analgesia required to be altered, this was done as per usual clinical practice.

Questionnaires: Brief Pain inventory (BPI). The BPI is a multi-dimensional pain assessment tool. It was designed to serve two purposes; to measure the intensity of pain and to assess the level of interference of pain on daily function. It was developed for use in cancer patients and has been extensively validated in both cancer and non-cancer patients [10, 3]. All questions in the BPI relate to the previous 24 hours. The section on pain intensity asks the worst, least and average pain as well as the pain right now. Subjects are asked to score each answer from 0-10 where 0 is “no pain” and 10 is “pain as bad as you can imagine”. It also asks the participant to rate the percentage of pain relief they experience from whatever pain treatments or medications they are currently on, ranging from 0-100.

The second section of the BPI focuses on the level of interference of pain on the subject’s lifestyle, namely their general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life. Again the scores are from 0-10 with 0 corresponding to “does not interfere” and 10 representing “completely interferes” with each question that has been asked.

Once the questionnaire has been completed, the total BPI score can be calculated and repeated to assess the impact of an intervention on the subject’s pain. For the study, the total score at baseline was calculated. A pain response was taken as a 30% drop in BPI score from the baseline assessment [3].

Short form McGill Pain Question (SF-MPQ) The MPG is a scale for assessing pain using verbal descriptors. It was designed to allow patients to express the intensity and quality of their pain [4]. A short form version was developed in 1987 [5], in 2009, this was further modified in order to develop a single measure for both neuropathic and non-neuropathic pain [6]. Amongst other purposes, it was planned that this questionnaire, SF- MPQ2, could be used in treatment response studies lead Assessment of Neuropathic symptoms and sign (LANS). The LANS was developed in 2001 as a tool to identify patients who are likely to have neuropathic pain [7]. It has been extensively validated [8, 9]. The assessment consists of two sections; a pain questionnaire and sensory testing. In the pain questionnaire, subjects are asked five yes/no questions concerning their pain. With the sensory testing, the subject is examined for alloying and for altered pin-prick threshold. Combining the scores for the questionnaire and the sensory testing gives a maximum score of 24. A score of >12 suggests that neuropathic mechanisms are likely to be contributing to the patient’s pain, whereas a score of <12 suggests that neuropathic mechanisms are unlikely to be contributing to the patient’s pain. Quality of Life Questionnaire (EORTC QLQ-C30): The EORTC QLQ-C30 is a validated questionnaire designed to assess the quality of life of cancer patients [11]. It incorporates nine multi-item scales: five functional scales (physical, role, cognitive, emotional and social); three symptom scales (fatigue, pain, and nausea and vomiting); and a global health and quality-of-life scale. As can be seen in the paragraphs above, with the exception of the NRS for night sweats, all of the questionnaires used in the study have been validated. The first step in the validation process involves a questionnaire being reposed.

Study Endpoints

Primary: As the primary aim of the prospective study was to examine if radiotherapy is an effective treatment for MBC, the primary endpoint was to assess if there was a clinically significant improvement in pain 5 weeks following radiotherapy. A clinically significant improvement in pain was defined as a > 30% reduction from baseline in total BPI score [3].

Secondary: There were a large number of secondary endpoints, all of which were exploratory in nature. The rationale for this was to inform future randomized studies examining radiotherapy in MBC. Endpoints were assessed at weeks 1, 5 and 12 weeks post radiotherapy with the primary analysis at week 5, unless otherwise stated.

Secondary endpoints were as follows: To examine the effect of radiotherapy on pain at weeks 1 and 12 post radiotherapy, assessed using the BPI. A clinically significant improvement in pain was defined as a > 30% reduction from baseline in total BPI score [10].

To examine the effect of radiotherapy on quality of life using the EORTC QLQ-C30 questionnaire (version 3.0) including lung cancer module EORTC QLQ-LC13.

The Results and Discussion

At weeks 1 and 12, the pain response rate was 27.5% (CI14.6%-43.9%) and 15.0% (CI5.7%-29.8%) respectively, on an intention to treat analysis. Based on complete case analysis, the proportion of pain responders at week 1 was 36.7% (CI19.9%-56.1%) and at week 12 was 33.3% (CI13.3%-59.0). Although 32 patients completed the week 1 Assessment, two of them had incomplete data and so were not evaluable. Eighteen patients were evaluable at week 12.
Pain characteristics

The sensory component of the SF-MPQ is shown in Figure 6, 7. The words most commonly chosen to describe the pain were aching, tender and sharp being reported by 32 (86.5%), 29(78.4%) and 27(73%) of patients respectively.
Figure 7 shows the individual components of the BPI. The median (IQR) for average pain and worst pain was 4 (4-6) and 8 (6-8) respectively. General activity, normal work and enjoyment of life scored the highest on the interference scores. Relationships appeared to be relatively unaffected by the pain.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Average lowest BPI Score</th>
<th>High base line answer</th>
<th>Low base line answer</th>
<th>Average higher BPI score</th>
</tr>
</thead>
<tbody>
<tr>
<td>worst</td>
<td>6</td>
<td>10</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>least</td>
<td>0.5</td>
<td>10</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>average</td>
<td>4</td>
<td>10</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>right now</td>
<td>1</td>
<td>10</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>general activity</td>
<td>5</td>
<td>10</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>mood</td>
<td>3</td>
<td>10</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>walking ability</td>
<td>3</td>
<td>10</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>work</td>
<td>4</td>
<td>10</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>relations</td>
<td>0.5</td>
<td>10</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>sleep</td>
<td>0.5</td>
<td>10</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>enjoyment</td>
<td>4</td>
<td>10</td>
<td>0</td>
<td>8</td>
</tr>
</tbody>
</table>

Table 3: LANSS score answer questionnaire

<table>
<thead>
<tr>
<th>Lanss score</th>
<th>No of patient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lanss score &gt;12</td>
<td>53</td>
</tr>
<tr>
<td>Lanss score &lt;12</td>
<td>33</td>
</tr>
</tbody>
</table>

Fifty-three patients, 31.4%, had a total LANSS >12 while 33 (68.6%) patients, had a LANSS <12. An analysis was performed to assess whether there was any association between total LANSS, BPI and MPQ.
The median total BPI for patients with a LANSS <12 was 52 (IQR 41.00 - 59.50) versus 69.50 (IQR 61.00 – 84.00) for patients with a LANSS >12, \( p=0.004 \). Similarly, comparing the LANSS with the SF-MPQ, the median SF-MPQ for those with a LANSS <12 was 10.00 (IQR 8.00 – 13.50) versus 15.00 (IQR 12.00– 18.00) for patients with a LANSS >12, \( p=0.012 \).

**CONCLUSION**

The study data was retrieved from patients’ files system of Radiation and Isotopes Center of Khartoum (RICK) which included patient age, grade, type of treatment, type of cancer cells and site of tumor MITS. They were followed for 12 weeks.

As can be seen from the short median survival of patients in the study, this is a frail population with poor life expectancy. Given that there were a number of questionnaires needing completed at each visit, it was felt to be in the patients’ best interests for a study researcher to help the patient complete the questionnaires. Although this is not how these questionnaires were validated, it proved to be a most useful decision as many patients found the help provided by the study researcher to be most useful.

The researcher used many model of stander international questionnaire such as Brief Pain inventory (BPI), which evaluate the pain in one to ten scale correspond with time duration. Short form McGill pain question (SFMPQ), consist of 15 description (11 sensor, 4 affective) the scale is from (0-4) in this study we used sensory component only lead Assessment of Neuropathic symptoms and sign (LANSS) which is pain questionnaires dived into section A complete by patient and section B complete by clinician. Each of these models corresponds with pain response rate, Quality of life and toxicity.

Ninety five patients were female and the median age (IQR) was 71.50 (35-55) years. The median survival from the time of trial registration was 93 days (CI 68-118). The Median (IQR) baseline BPI score was 57 (42.0-65.5).

There are many methods to measure it, such as direct method, actuarial method and Kalban-Meier method. First measure by the Direct Method (appendix-vital status data sheet), it’s the simplest way of summarizing patient survival, by calculate the percentage of patients alive at the end of a specified interval such as 12 weeks, for the 100 patients at risk for at 12 weeks indicates that 39 Patients were alive at last contact and 61 had died before week 12.

Palliative radiotherapy play important role in management of pain, we can evaluation the benefit of radiotherapy in palliative cases by a set of international standards questionnaire by which the calibration of the result. A major goal of palliative radiotherapy is control the symptoms by given the tumor dose the lethal dose with simple treatment planning and treatment.
patient’s symptoms such as pain, compression symptoms can be controlled by radiotherapy.

**Recommendations**

- Implantation of stander palliative radiotherapy program in each oncology hospital play important role in success the RT treatment
- The time is important factor which effect in patients response, time between the symptoms appearance and treat with first session.
- The radiotherapy regime which describe the suitable field size with minimum number of fraction should be chosen
- Radiotherapy for pain controlled recommend because of high response and low side effect.

**Acknowledgment**

I am most of all grateful to the God, who made me able to fulfill this PhD thesis in spite of all problem and pressure. Profound thanks and gratitude to everyone who encouraged me to complete this thesis. I named my thesis to all breast cancer patients fighting and win, My parents, my husband and my kids whose prayers and support has always contributed to my success. My supervisor professor Mohamed Alfadil and Dr Nahla gafer deserves all my gratitude as I could not have made it through without his invaluable support.

**REFERENCES**